-
Something wrong with this record ?
Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities
Z. Novakova, J. Cerny, CJ. Choy, JR. Nedrow, JK. Choi, J. Lubkowski, CE. Berkman, C. Barinka,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2005 to 1 year ago
Medline Complete (EBSCOhost)
from 2005-01-01 to 1 year ago
Wiley Free Content
from 2005 to 1 year ago
PubMed
26460595
DOI
10.1111/febs.13557
Knihovny.cz E-resources
- MeSH
- Amides chemical synthesis chemistry pharmacology MeSH
- Antigens, Surface metabolism MeSH
- Glutamate Carboxypeptidase II antagonists & inhibitors metabolism MeSH
- Enzyme Inhibitors chemical synthesis chemistry pharmacology MeSH
- Crystallography, X-Ray MeSH
- Phosphoric Acids chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Models, Molecular MeSH
- Molecular Structure MeSH
- Drug Design * MeSH
- Hydrogen Bonding MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
UNLABELLED: Inhibitors targeting human glutamate carboxypeptidase II (GCPII) typically consist of a P1' glutamate-derived binding module, which warrants the high affinity and specificity, linked to an effector function that is positioned within the entrance funnel of the enzyme. Here we present a comprehensive structural and computational study aimed at dissecting the importance of the effector function for GCPII binding and affinity. To this end we determined crystal structures of human GCPII in complex with a series of phosphoramidate-based inhibitors harboring effector functions of diverse physicochemical characteristics. Our data show that higher binding affinities of phosphoramidates, compared to matching phosphonates, are linked to the presence of additional hydrogen bonds between Glu424 and Gly518 of the enzyme and the amide group of the phosphoramidate. While the positioning of the P1' glutamate-derived module within the S1' pocket of GCPII is invariant, interaction interfaces between effector functions and residues lining the entrance funnel are highly varied, with the positively charged arginine patch defined by Arg463, Arg534 and Arg536 being the only 'hot-spot' common to several studied complexes. This variability stems in part from the fact that the effector/GCPII interfaces generally encompass isolated areas of nonpolar residues within the entrance funnel and resulting van der Waals contacts lack the directionality typical for hydrogen bonding interactions. The presented data unravel a complexity of binding modes of inhibitors within non-prime site(s) of GCPII and can be exploited for the design of novel GCPII-specific compounds. PDB ID CODES: Atomic coordinates of the present structures together with the experimental structure factor amplitudes were deposited at the RCSB Protein Data Bank under accession codes 4P44 (complex with JRB-4-81), 4P45 (complex with JRB-4-73), 4P4B (complex with CTT54), 4P4D (complex with MP1C), 4P4E (complex with MP1D), 4P4F (complex with NC-2-40), 4P4I (complex with T33) and 4P4J (complex with T33D).
Department of Chemistry Washington State University Pullman WA USA
Institute of Biotechnology Academy of Sciences of the Czech Republic Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020222
- 003
- CZ-PrNML
- 005
- 20160805120617.0
- 007
- ta
- 008
- 160722s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/febs.13557 $2 doi
- 024 7_
- $a 10.1111/febs.13557 $2 doi
- 035 __
- $a (PubMed)26460595
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Novakova, Zora $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities / $c Z. Novakova, J. Cerny, CJ. Choy, JR. Nedrow, JK. Choi, J. Lubkowski, CE. Berkman, C. Barinka,
- 520 9_
- $a UNLABELLED: Inhibitors targeting human glutamate carboxypeptidase II (GCPII) typically consist of a P1' glutamate-derived binding module, which warrants the high affinity and specificity, linked to an effector function that is positioned within the entrance funnel of the enzyme. Here we present a comprehensive structural and computational study aimed at dissecting the importance of the effector function for GCPII binding and affinity. To this end we determined crystal structures of human GCPII in complex with a series of phosphoramidate-based inhibitors harboring effector functions of diverse physicochemical characteristics. Our data show that higher binding affinities of phosphoramidates, compared to matching phosphonates, are linked to the presence of additional hydrogen bonds between Glu424 and Gly518 of the enzyme and the amide group of the phosphoramidate. While the positioning of the P1' glutamate-derived module within the S1' pocket of GCPII is invariant, interaction interfaces between effector functions and residues lining the entrance funnel are highly varied, with the positively charged arginine patch defined by Arg463, Arg534 and Arg536 being the only 'hot-spot' common to several studied complexes. This variability stems in part from the fact that the effector/GCPII interfaces generally encompass isolated areas of nonpolar residues within the entrance funnel and resulting van der Waals contacts lack the directionality typical for hydrogen bonding interactions. The presented data unravel a complexity of binding modes of inhibitors within non-prime site(s) of GCPII and can be exploited for the design of novel GCPII-specific compounds. PDB ID CODES: Atomic coordinates of the present structures together with the experimental structure factor amplitudes were deposited at the RCSB Protein Data Bank under accession codes 4P44 (complex with JRB-4-81), 4P45 (complex with JRB-4-73), 4P4B (complex with CTT54), 4P4D (complex with MP1C), 4P4E (complex with MP1D), 4P4F (complex with NC-2-40), 4P4I (complex with T33) and 4P4J (complex with T33D).
- 650 _2
- $a amidy $x chemická syntéza $x chemie $x farmakologie $7 D000577
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
- 650 _2
- $a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $x metabolismus $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a vodíková vazba $7 D006860
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a kyseliny fosforečné $x chemická syntéza $x chemie $x farmakologie $7 D010756
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cerny, Jiri $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Choy, Cindy J $u Department of Chemistry, Washington State University, Pullman, WA, USA.
- 700 1_
- $a Nedrow, Jessie R $u Department of Chemistry, Washington State University, Pullman, WA, USA.
- 700 1_
- $a Choi, Joeseph K $u Department of Chemistry, Washington State University, Pullman, WA, USA.
- 700 1_
- $a Lubkowski, Jacek $u National Cancer Institute, Center for Cancer Research, Macromolecular Crystallography Laboratory, Frederick, MD, USA.
- 700 1_
- $a Berkman, Clifford E $u Department of Chemistry, Washington State University, Pullman, WA, USA.
- 700 1_
- $a Barinka, Cyril $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 773 0_
- $w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 283, č. 1 (2016), s. 130-43
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26460595 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160805120849 $b ABA008
- 999 __
- $a ok $b bmc $g 1154892 $s 944750
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 283 $c 1 $d 130-43 $e 20151105 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
- LZP __
- $a Pubmed-20160722